Articles By Wayne Koberstein
-
Blockbuster Drugs – Time For A Revival?
6/1/2012
Targeted drugs and personalized medicines are supposed to be an alternative for blockbuster drugs but who the future belongs to is the high-stakes question of innovator companies. By Wayne Koberstein, Contributing Editor
-
Speeding Up The Evolution Of Personalized Medicine
6/1/2012
FDA Special Advisor, Dr. Vicki Seyfert-Margolis has a strategic innovation plan to prepare and equip the FDA for supporting personalized medicine. By Wayne Koberstein, Contributing Editor
-
Top 10 Pitfalls Of Life Sciences Partnering: Part 1
4/30/2012
The mandates to serialize all pharmaceutical products are as challenging for pharmaceutical manufacturers as the Y2K situation was to computer software engineers.
-
Personalized Medicine — Snapshot Of An Early Race
9/12/2011
One important caveat of the Diaceutics report is omission of key criteria: planning and intent. Have companies that launched themselves furthest into PM done so from an a priori belief in the concept or because they were reacting to untoward developments — such as efficacy and safety problems emerging for products already on the market? By Wayne Koberstein
-
Leader In Transition
6/9/2011
Total dedication to job and family leaves little room for distractions. “The reason I don’t have any hobbies is that I spend all my free time with my family,” says Carrie Cox. By Wayne Koberstein, Life Science Leader magazine